Loading
RBM10 (Ribosome biogenesis inhibitor MINAS-60) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and 4 more.
Acts as a late-stage inhibitor of pre-60S ribosome assembly by preventing pre-60S ribosome export from nucleus.
Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes literature 0.98, animal model 0.43, genetic association 0.00, somatic mutation 0.97). IntOGen calls it a driver in 16 cohorts (1 activating, 15 loss-of-function), covering Bladder Urothelial Carcinoma, Cholangiocarcinoma, Colorectal Adenocarcinoma, Lung Adenocarcinoma, Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma.
In plain words · RBM10 (Ribosome biogenesis inhibitor MINAS-60) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and 4 more.
RBM10 (Ribosome biogenesis inhibitor MINAS-60) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and 4 more.
Acts as a late-stage inhibitor of pre-60S ribosome assembly by preventing pre-60S ribosome export from nucleus. Location: Nucleus, nucleolus (UniProt).
No product in this corpus aims at RBM10 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
First described 2004. Earliest sequence paper UniProt cites for the protein: Genome Res, 2004, "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)". Source.
Sources: HGNC HGNC:9896 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P0DW28 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000182872 (association with cancer (MONDO_0004992) 0.75; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.69, colorectal cancer 0.60, urinary bladder cancer 0.59, lung cancer 0.69, biliary tract cancer 0.58 (GraphQL API, CC0)); IntOGen RBM10 (driver in 16 cohorts (Act 1, LoF 15); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Acts as a late-stage inhibitor of pre-60S ribosome assembly by preventing pre-60S ribosome export from nucleus. Location: Nucleus, nucleolus (UniProt). Locus Xp11.3 (HGNC).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Non-small-cell lung cancer | 7-11% | Inactivating mutation (splicing regulator) | cBioPortal: 294 of 2,653, 11.1%, in luad_mskcc_2023_met_organotropism; 78 of 915, 8.5%, in lung_msk_2017; 38 of 566, 6.7%, in luad_tcga_pan_can_atlas_2018; 19 of 230, 8.3%, in luad_tcga_pub; 22 of 302, 7.3%, in luad_oncosg_2020; 17 of 232, 7.3%, in lung_nci_2022; 6 of 484, 1.2%, in lusc_tcga_pan_can_atlas_2018. | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Query for this target: (TITLE:"RBM10" OR ABSTRACT:"RBM10" OR TITLE:"RNA binding motif protein 10" OR ABSTRACT:"RNA binding motif protein 10" OR TITLE:"Ribosome biogenesis inhibitor MINAS-60" OR ABSTRACT:"Ribosome biogenesis inhibitor MINAS-60" OR TITLE:"DXS8237E" OR ABSTRACT:"DXS8237E" OR TITLE:"KIAA0122" OR ABSTRACT:"KIAA0122" OR TITLE:"GPATC9" OR ABSTRACT:"GPATC9") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RBM10, not a curated reading list.
Shares Biliary tract cancer (all types), Bladder & urothelial cancer, IntOGen, Lung cancer (all types).
Shares Comprehensive molecular profiling of lung adenocarcinoma, IntOGen, Lung cancer (all types), Open Targets Platform.
Shares Biliary tract cancer (all types), IntOGen, Lung cancer (all types), Open Targets Platform.
Shares Biliary tract cancer (all types), IntOGen, Open Targets Platform, Pancreatic ductal adenocarcinoma.
Shares Biliary tract cancer (all types), IntOGen, Open Targets Platform, Colorectal cancer.
Shares Biliary tract cancer (all types), IntOGen, Open Targets Platform, Colorectal cancer.
Shares Comprehensive molecular profiling of lung adenocarcinoma, Non-small-cell lung cancer.
Shares Comprehensive molecular profiling of lung adenocarcinoma, IntOGen, Non-small-cell lung cancer.